C Gridelli
Overview
Explore the profile of C Gridelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
1655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Groen H, Socinski M, Grossi F, Juhasz E, Gridelli C, Baas P, et al.
Ann Oncol
. 2013 Jun;
24(9):2382-9.
PMID: 23788751
Background: Combined inhibition of vascular, platelet-derived, and epidermal growth factor receptor (EGFR) pathways may overcome refractoriness to single agents in platinum-pretreated non-small-cell lung cancer (NSCLC). Patients And Methods: This randomized,...
12.
Peters S, Adjei A, Gridelli C, Reck M, Kerr K, Felip E
Ann Oncol
. 2012 Sep;
23 Suppl 7:vii56-64.
PMID: 22997455
No abstract available.
13.
Rossi A, Gridelli C, Ricciardi S, de Marinis F
Curr Med Chem
. 2012 Sep;
19(32):5524-35.
PMID: 22963665
About 30-40% of patients affected by non-small cell lung cancer (NSCLC) develop, during the course of their disease, bone metastases. The prognosis of these patients is poor with a median...
14.
Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, et al.
Curr Med Chem
. 2012 Jun;
19(20):3337-52.
PMID: 22664249
Lung cancer continues to be the leading cause of cancer death worldwide. Among lung cancers, 80% are classified as nonsmall- cell lung cancer (NSCLC) and are mostly diagnosed at an...
15.
Schettino C, Bareschino M, Rossi A, Maione P, Sacco P, Colantuoni G, et al.
Curr Cancer Drug Targets
. 2012 Jan;
12(3):289-99.
PMID: 22229249
Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all new lung cancer diagnosis. The majority of people...
16.
Bareschino M, Schettino C, Colantuoni G, Rossi E, Rossi A, Maione P, et al.
Curr Med Chem
. 2011 Nov;
18(33):5022-32.
PMID: 22050750
Angiogenesis is known to be essential for the development and progression of cancer. Vascular endothelial growth factor (VEGF) is a critical mediator in tumor angiogenesis for many solid malignancies, including...
17.
Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer J, Georgoulias V, et al.
Ann Oncol
. 2011 Sep;
23(5):1223-1229.
PMID: 21940784
The current third consensus on the systemic treatment of non-small-cell lung cancer (NSCLC) builds upon and updates similar publications on the subject by the Central European Cooperative Oncology Group (CECOG),...
18.
Felip E, Gridelli C, Baas P, Rosell R, Stahel R
Ann Oncol
. 2011 May;
22(7):1507-1519.
PMID: 21536661
The 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21 and 22 May 2010 with the participation of a multidisciplinary panel of leading professionals in...
19.
Gridelli C, Ianniello G, Ambrosini G, Mustacchi G, Pedicini T, Farris A, et al.
Int J Oncol
. 2011 May;
10(2):395-400.
PMID: 21533390
The aim was to compare the efficacy of ondansetron and a combination of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis over three consecutive courses of chemotherapy. Cancer...
20.
Gridelli C, de Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T
Lung Cancer
. 2011 Jan;
72(1):3-8.
PMID: 21216488
Randomized trials comparing gefitinib with chemotherapy as first-line treatment in patients with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment option in this setting. However, its...